Advertisement

First Indian Study on Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Advanced Peritoneal Carcinomatosis Secondary to Epithelial Ovarian Cancer

  • S. P. Somashekhar
  • Ashwin Kyatsandra Rajagopal
  • Shabber S. Zaveri
  • Rohit Kumar Chandrashekhar
  • Amit Rauthan
  • Sushmita H. Rakshit
Original Article
  • 20 Downloads

Abstract

Background

Peritoneal carcinomatosis is a common evolution in ovarian cancers. Although majority of patients have option of cytoreductive surgery and HIPEC, a few with recurrent cancers who are not eligible for curative approach can undergo pressurized intraperitoneal aerosol chemotherapy (PIPAC) which is an emerging field of research with major therapeutic potential. It is a safe and innovative approach, which enhances the effect of chemotherapy without major toxicity.

Methods

Between June 2017 and December 2017, 9 PIPAC applications in 3 patients with pressurized aerosol solution of cisplatin and doxorubicin every 6 weeks at 37 °C and 12 mmHg for 30 min were performed. The patient demographics, perioperative findings, adverse events, and outcomes were prospectively recorded.

Results

Nine PIPAC administrations were performed in 3 patients with peritoneal carcinomatosis secondary to ovarian cancer. The median hospital stay was 1 day. There were no major perioperative complications. CTCAE grade 2 was observed in 1 patient, for abdominal pain and nausea. Renal and hepatic functions were not impaired. Of the 3 patients, two patients had partial response, and one had stable disease.

Conclusion

Our results show the feasibility and safety of PIPAC in Indian patients with advanced ovarian cancer. The procedure has low morbidity with no mortality with short learning curve. It can be easily adopted as a palliative option apart from systemic chemotherapy.

Keywords

PIPAC Peritoneal carcinomatosis Indian patients CRS HIPEC Intraperitoneal Chemotherapy Ovarian cancer 

Notes

Compliance with ethical standards

conflict of interest

The authors declare that, they have no conflict of interest

References

  1. 1.
    Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996;82:79–100.  https://doi.org/10.1007/978-1-4613-1247-5_6.CrossRefPubMedGoogle Scholar
  2. 2.
    Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13(8):e362–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Beckert S, Struller F, Grischke EM, Glatzle J, Zieker D, Königsrainer A, Königsrainer I. Surgical management of peritoneal surface malignancy with respect to tumour type, tumour stage and individual tumour biology. ZentralblChir. 2013; [Epub ahead of print] German.Google Scholar
  4. 4.
    Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7:596–603.  https://doi.org/10.1097/00001813-199607000-00016.CrossRefPubMedGoogle Scholar
  5. 5.
    Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg. 2012;256:1084–8.  https://doi.org/10.1097/SLA.0b013e3182582b38.CrossRefPubMedGoogle Scholar
  6. 6.
    Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:106–12.  https://doi.org/10.1097/01.sla.0000218089.61635.5f.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.  https://doi.org/10.1038/nrc1893.CrossRefPubMedGoogle Scholar
  8. 8.
    Tempfer CB, Winnekendonk G, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137(2):223–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016;18(4):364–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26:847–52.  https://doi.org/10.1007/s00464-011-1964-y.CrossRefPubMedGoogle Scholar
  14. 14.
    Solaß W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849–55.  https://doi.org/10.1007/s00464-012-2148-0.CrossRefPubMedGoogle Scholar
  15. 15.
    Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20:2311–6.  https://doi.org/10.1245/s10434-012-2840-2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Solass W, Sempoux C, Carr NJ, Detlefsen S, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Perit. 2016;1:99–107.Google Scholar
  19. 19.
    Tempfer CB, Celik I, Solass W, et al. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132(2):307–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98:1225–35.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2018

Authors and Affiliations

  • S. P. Somashekhar
    • 1
  • Ashwin Kyatsandra Rajagopal
    • 1
  • Shabber S. Zaveri
    • 1
  • Rohit Kumar Chandrashekhar
    • 1
  • Amit Rauthan
    • 2
  • Sushmita H. Rakshit
    • 3
  1. 1.Department of Surgical Oncology, Manipal Comprehensive Cancer CenterManipal HospitalBangaloreIndia
  2. 2.Department of Medical Oncology, Manipal Comprehensive Cancer CenterManipal HospitalBangaloreIndia
  3. 3.Pathology DepartmentManipal HospitalBangaloreIndia

Personalised recommendations